Compass Therapeutics, Inc. Share Price OTC Markets
Equities
CMPX
US20454B1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -10.80% |
|
+32.67% | -.--% |
28/05 | Compass Therapeutics Appoints Thomas Schuetz as CEO | MT |
28/05 | Compass Therapeutics, Inc. Announces CEO Changes | CI |
Sales 2024 * | - | Sales 2025 * | 53.29L 44Cr | Capitalization | 14Cr 1.15TCr |
---|---|---|---|---|---|
Net income 2024 * | -5.4Cr -450.01Cr | Net income 2025 * | -7.1Cr -591.68Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 25.8 x |
P/E ratio 2024 * |
-2.58
x | P/E ratio 2025 * |
-2.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.96% |
1 day | -10.80% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Schuetz
CEO | Chief Executive Officer | 63 | 01/14/01 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 01/20/01 |
Karin Herrera
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 21/23/21 |
Mary Gray
BRD | Director/Board Member | 71 | 25/22/25 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 25/22/25 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- CMPX Stock
- CMPX Stock